Snell & Wilmer

LAW OFFICES

1920 Main Street, Suite 1200 Irvine, California 92614-7060

> (949) 253-2700 Fax: (949) 955-2507 www.swlaw.com

RECEIVED
CENTRAL FAX GENTER

SEP 2 8 2004

IRVINE, CALIFORNIA

PHOENIX, AKIZONA

TUCSON, ARIZONA

SALT LAKE CITY, UTAH

DENVER, COLORADO

LAS VEGAS, NEVADA

FACSIMILE TRANSMISSION

DATE:

September 28, 2004

TIME IN: TIME OUT:

TO

Marne	Fax Number	Phone Member
USPTO	703-872-9603 9306	
Examiner Gabel USPTO	571-273-0820	571-272-0820

FROM:

Joseph W. Price

PHONE:

949-253-4920

MESSAGE:

RE: 09/511,824

Attorney Docket: 42479-2500

Please see attached Terminal Disclaimer and accompanying transmittals.

Thank you.

PLEASE CONFIRM RECEIPT VIA RETURN FAX

ORIGINAL DOCUMENT:

NUMBER OF PAGES (Including Cover):

•

CONFIRMATION NO.:

CLIENT MATTER NO.:

99999-0000

PLEASE RETURN TO:

Sharon Farnus

PERSONAL FAX:

No

REQUESTOR:

Joseph W. Price

DIRECT LINE:

949-253-4920

IF YOU HAVE NOT PROPERLY RECEIVED THIS TELECOPY, PLEASE CALL US AT (949) 253-2791.

OUR FACSIMILE NUMBER IS (949) 955-2507.

THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS ATTORNEY PRIVILEGED AND CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY NAMED ABOVE. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US AT THE ABOVE ADDRESS VIA THE U.S. POSTAL SERVICE. THANK YOU.

	Docket No. 42479-2500						
In Re Application Of: Yasue Yamae et al.							
Serial No.	Filing Date	Examiner Group Art					
09/511,824	02.24.2000	Gailene Gabel		1641			
Title: IMMUNOASSAY METHOD FOR LYSED WHOLE BLOOD RECEIVED CENTRAL FAX CENTER SEP 2 8 2004							
	TO THE COMMISS	IONER FOR PATENTS:					
Transmitted herewith is:							
Letter to Examiner Re Fee Transmittal Terminal Disclaimer	Submission of Terminal Disclaim	er					
in the above identified application. No additional fee is required. A check in the amount of is attached. The Director is hereby authorized to charge and credit Deposit Account No. as described below. Charge the amount of \$110.00 Credit any overpayment. Charge any additional fee required.							
Joseph W. Price Reg. No. 25,124 SNELL & WILMER, LLP 1920 Main Street, Suite 1200 Irvine, CA 92614 Tel: 949-253-4920 Fax: 949-955-2507 Customer No. 21611 Dated: September 28, 2004 I hereby certify that this correspondence is being sent via Facsimile at 703-872-9306 to Gailene Gabel, at the USPTO on September 28, 2004 By: Sharon Farnus Signature Dated: September 28, 2004							

PTO/SB/17 (10-03)

Approved for use through 07/31/2006. On	MB 0851-003
Patent and Trademark Office: U.S. DEPARTMENT OF	COMMERC
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid	d OMB contro

(FEE TRANSMITTAL!				Complete it Midwit							
			Application Number 09/511								
for FY 2004		- ↓	Filing Date			_	62.24.2000				
Effective 10/01/2003. Patent fees are subject to annual revision.		Q17.	First Named Inventor				Yamao, Yasuo				
Applicant claims small entity status. See 37 CFR 1.27		7	Examiner Name Gabe			Gabel,	, Gallene				
	A) 0110		Art U	-			1641				
TOTAL AMOUNT OF PAYMENT	\$) \$110	1.00)	Attor	ney D	ocket N	No. 4	42749-2	2500		31574	
METHOD OF PAYMENT (check	all that opply)				FE	E CALC	CULA'	TION (co	ntinued)		
Check Credit card Mone Other None 3. ADDITIONAL FEES											
Deposit Account:		Large Fee	Fee	Smal Fee	LEntity Foe				_		
Daposit		Code	(\$)	Code	(\$)	Cushasa		Descriptio			Fee Pald
Account 19-2814		1051	130	2051		_		filing fee o			
Deposit Account Snell & Wilmer L.		1052	50	2052	25	sheet	18 - 18NB	bi ovisioi itii	filing fee o	CTIARL	L
Name Sitell & Willief La	OI.	1053	130	1053	130	Non - En	glish sp	edification			
The Director is authorized to: (check all that app	nby)	1812	•		•	_	•		arto reexem	ination	
Charge fee(s) indicated below Credit any or	verpayments	1804	920*	1804	920*	Requesti	ng publi r action	lcation of S	IR prior to		
Charge any additional fee(s) or any underpayment of		1805	1,840*	1805	1,840*				IR after Exa	miner	
Charge fee(s) indicated below, except for the filing	foo	1251	110	2251	55		n for rec	Dy within fir	st month		
to the above-Identified deposit account.		1252	420	2252			•		scand mant	h	
FEE CALCULATION		1253	950	2253	475	Extension	n for rep	aly within th	ird month		
1. BASIC FILING FEE		1264	1,480	2254	740	Extension	n for rep	oly within fo	urth month		
Fee Fee Fee Fee Description	Fee Paid	1255	2,010	2255	1,005	Extension	n for rep	oly within fif	th month		
Code (\$) Code (\$) 1001 770 2001 385 Utility filing fee	rao raio	1401	330	2401	165	Notice of	Appeal	1			
1002 340 2002 170 Design filing fee		1402	330	2402	165	Filing a b	rlefin s	upport of a	n eppeal		
1003 630 2003 265 Plant filing fee		1403	290	2403	145	Request	for oral	hearing			
1004 770 2004 385 Reissue filing		1451	1,510	1451	1,510	Petition b	utitani o	ite a public	nse bloces	ding	
1005 160 2006 80 Provisional filing fee		1452	110	745Z	55	Petition t	o toviva	· unavolda	abto	•	
SUBTOTAL (1) (\$)		1453	1,330	2453	665	Petition to	o revive	- unintenti	onal		
2. EXTRA CLAIM FEES FOR UTILITY A		1501	1,330	2501	865			(or release)			
Fee fro	om c	1502	480	2502	240	Design is		•			
Extra Claims belo	W 0.00	1503	640	2503	320	Plant Issu					
Independent3** = 0 X	□ □ 0.00	1460	130	1460	130			Commission			
Ctalrins Multiple Depandent	_ =	1807	50	1807	50		_		FR § 1.17(9)	<u> </u>
Lerge Entity Small Entity		1806	180	1806	180	Statemer	nt	dormation i			
Fee Fee Fee Fee Fee Description Code (\$) Code (\$)	חכ	8021	40	8021	40	Recordin	g each	patent ass	gnment per eropenies)	•	
1202 18 2202 9 Claims in excess of 2	20	1809	770	2809	385	Filing a a	ubmiss	ion after fin	al rejection		
1201 86 2201 43 Independent claims i	n excess of 3	1810	770	2810	385	(37 CFR			n to be exa	mined	
1203 290 2203 145 Multiple dependent c	laim, if not paid		770			(37 CFR	§ 1.12	29(b))			
1204 88 2204 43 ** Reissue Independe		1801	770	2801		•			mination (R	CE)	
over original patein 1205 18 2205 9 ** Reissue claims in		1802	900	1802	900	Request of a deal	tor expo gn appli	edited exam leation	nination		
and over original p	er foe (specify) <u>Term</u>	inal Disch					110.00		
SUBTOTAL (2) (8	\$0. 00								•		
		•Re	duced t	y Basi	c Filina	Fee Paid		SUBTO	TAL (3)	(\$)	\$110.00
"or number previously paid, if greater, For Reiss	uga, ann andya			-			_	Complete /	if annih-bi-1	17/	
SUBMITTED BY	$\overline{\mathcal{L}}$	1	Registr	ation N	0.	45.15.		Complete (040 981 4	220
Name Toseph W. P			(Attorne)			25,124		Telephon		949-253-4	241
Signature St. C.	/ Jus							Date	Septi	mber 28,	2004

WARNING: Information on this form may become public. Credit card information should

mot be included on this form may become public. Credit card information and authorization on

not be included on this form. Provide credit card information and authorization on

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or rotain a benefit by the public which is to tile (and by
the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to
complete, including gathering, presenting the complete this form to the USPTO. Time will vary depending upon the individual case.
Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information
Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR
COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need exsistance in completing the form, call 1-800-PTO-9199 and select option 2.

T-905 P. 04/06 F-246

SEP 2 8 2004

Patent 42479-2500

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Patent Examiner: Gailene Gabel

Yasuo Yamao, et al.

Group Art Unit: 1641

Serial No.: 09/511,824

Filed: February 24, 2000

September 28, 2004

For:

IMMUNOASSAY METHOD

FOR LYSED WHOLE BLOOD

Irvine, California 92614

LETTER TO EXAMINER RE SUBMISSION OF TERMINAL DISCLAIMER

VIA FACSIMILE

703-872-9306

ATTN: EXAMINER GAILENE GABEL

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Examiner Gabel:

In accordance with your telephone request, attached hereto is an executed Terminal Disclaimer for the parent U.S. Patent 6,030,845.

It is my understanding that this should place the case in condition for allowance and that it will not be necessary for us to proceed forward to file an appeal brief.

I wish to thank you for your courtesy in addressing this issue and bringing it to our attention.

1

Patent 42479-2500

If there are any questions please contact the attorney at the telephone number below.

I hereby certify that this correspondence is being sent via Facsimile at 703-872-9306 to Gailene Gabel, at the USPTO on September 28, 2004

By: Sharon Farnus

Signature

Dated: September 28, 2004

Very truly yours,

SNELL & WILMER L.L

Joseph W. Price

Begistration No. 25,124

1920 Main Street, Suite 1200

Irvine, California 92614-7230

Telephone: (949) 253-4920

Termina Patenti	Docket No. 42479-2500							
In Re Application Of: Yasuo Yamao et al.								
Serial No. 09/511,824	Filing Date 02.24.2000	Examiner Group Art Unit Gallene Gabel 1641						
Invention: IMMUNOASSAY METHOD FOR LYSED WHOLE BLOOD RECEIVED CENTRAL FAX CENTER								
Owner of Record: Horiba, Ltd.								
The above-identified owner of record of a 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 158 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,030,845. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors and/or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later expires for fallure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer. Check either box 1 or 2 below, if appropriate. 1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization. I hereby declere that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and								
the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent Issued thereon. 2. The undersigned is an attorney of record. Dated: September 28, 2004 Signature Joseph W. Price Typed or Printed Name Terminal disclaimer fee under 37 C.F.R. 1.20(d) included. PTO suggested wording for terminal disclaimer was unchanged. Certification under 37 C.F.R. 3.73(b) is required if terminal disclaimer is signed by the assignee.								